9.5亿美元！京企创新药出海授权再达成新交易

Group 1 - Beijing-based innovative pharmaceutical company BeiGene announced an agreement with Royalty Pharma to sell the rights to receive royalties from the global sales of the drug Talazoparib outside of China, with a maximum transaction value of $950 million [1] - According to the agreement, BeiGene will receive an upfront payment of $885 million and has the option to sell the remaining royalty rights within 12 months for an additional payment of up to $65 million [1] - Talazoparib is a first-in-class immunotherapy that targets DLL3 protein on tumor cells and CD3 protein on T cells, activating T cells to kill DLL3-expressing tumor cells, and has been approved in the U.S. for treating extensive-stage small cell lung cancer [1] Group 2 - This year, Beijing's innovative pharmaceutical companies have been active in overseas licensing deals, generating significant revenue and enhancing self-sustainability [2] - Earlier this year, companies Innovent Biologics and Connaissance Therapeutics entered into a licensing agreement with Prolium Bioscience for the development and commercialization of a bispecific antibody, ICP-B02, with a total payment of up to $520 million [2] - The licensing fees from this agreement helped Innovent Biologics achieve its first quarterly profit in the first quarter of this year [2]